Since the introduction of interferon beta-1b in 1993, the number of disease-modifying therapies for multiple sclerosis (MS) has grown at a remarkable pace. Currently there are 10 treatments approved by the US Food and Drug Administration, each with varying effects on important clinical and radiographic markers of disease activity.
Multiple sclerosis is one of many immune-mediated diseases in which significant advancements in disease modification have been made. Tumor necrosis factor inhibitors have revolutionized the treatment of rheumatologic diseases such as Crohn disease, psoriasis, and rheumatoid arthritis (RA). This therapeutic class has made sustained disease remission achievable in these rheumatologic diseases. In the case of RA, combinations of clinical and laboratory measures such as disease activity status became the standard by which treatment success is measured.1
Bevan CJ, Cree BAC. Disease Activity Free StatusA New End Point for a New Era in Multiple Sclerosis Clinical Research?. JAMA Neurol. 2014;71(3):269-270. doi:10.1001/jamaneurol.2013.5486